Results 161 to 170 of about 22,889 (244)

Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes. [PDF]

NAR Cancer
Heer CD, Elia JL, Menon V, Johnson SS, Arbelaez SR, Friedman S, Lopez-Giraldez F, Sundaram RK, Herzon SB, Bindra RS, Gueble SE.   +10 more
europepmc   +1 more source

Transcriptomic Analysis of TDP1-Knockout HEK293A Cells Treated with the TDP1 Inhibitor (Usnic Acid Derivative). [PDF]

Int J Mol Sci
Zakharenko AL, Dyrkheeva NS, Markov AV, Kleshchev MA, Ryabchikova EI, Malakhova AA, Orishchenko KE, Okorokova LS, Shtokalo DN, Medvedev SP, Zakian SM, Tupikin AA, Kabilov MR, Luzina OA, Deyev SM, Lavrik OI.   +15 more
europepmc   +1 more source

Validating TDP1 as an Inhibition Target for Lipophilic Nucleoside Derivative in Human Cells. [PDF]

Int J Mol Sci
Chernyshova IA, Kornienko TE, Dyrkheeva NS, Zakharenko AL, Chepanova AA, Orishchenko KE, Kurochkin NN, Drenichev MS, Lavrik OI.   +8 more
europepmc   +1 more source

Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis. [PDF]

Front Immunol
Zhou J, Ye W, Ranarisoa SN, Tian L.
europepmc   +1 more source

The Efficacy and Safety of Nab-Paclitaxel Plus Anlotinib in Small-Cell Lung Cancer for Second-Line Therapy. [PDF]

Thorac Cancer
Tian LJ, Zhou FF, Dai M, Liu JL, Guo QS.
europepmc   +1 more source

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. [PDF]

J Cancer Res Clin Oncol
Janke FF, Baldessarini RJ, Bauerschlag D, Zibolka S, Hartmann M.   +4 more
europepmc   +1 more source

Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer - a grade-assessed network meta-analysis of randomized controlled trials. [PDF]

BMC Cancer
Najah Q, Makhlouf HA, Osman ASA, Almosilhy NA, Abusalah MA, Abuhlaiga MA, Qutob IA, Abdelgawad HAH.   +7 more
europepmc   +1 more source

Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. [PDF]

J Clin Med
Acar O, Agaoglu AB, Sahbazlar M, Ekinci F, Erdogan AP.   +4 more
europepmc   +1 more source